Could your own cells fix your shoulder arthritis?

NCT ID NCT02844738

Recruiting now Symptom relief Sponsor: VivaTech International, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a treatment made from a patient's own cells (StroMed) and platelet-rich plasma can reduce pain and inflammation from shoulder osteoarthritis. The first 50 participants will receive injections, and then up to 4,000 more will join to confirm safety and effectiveness. Researchers will track changes in shoulder function, pain, and even look for cartilage regrowth on MRI scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: StroMed (a patient's own regenerative cells) plus platelet-rich plasma (PRP)
What this could lead to: If it works, this could offer a new way to reduce pain and improve shoulder function without surgery or long-term medication.
What could go wrong: This is an early Phase 2 study with no placebo group, so results may be due to chance. The larger follow-up may not confirm benefits, and risks like infection or injection-site reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOARTHRITIS

Contacts and locations

Locations

VivaTech International, Inc.
RECRUITING

Grove City, Pennsylvania, 16127, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.